Last updated: February 9, 2026
What is the scope of the case?
The case involves patent infringement allegations filed by Natera, Inc., against CareDx, Inc., over claims related to diagnostic testing technology. Natera accuses CareDx of infringing two patents—U.S. Patent No. 9,617,284 and U.S. Patent No. 10,552,519—which cover methods involved in cell-free DNA testing for organ transplant monitoring.
When did the case begin, and what are the key procedural milestones?
-
Filing date: January 2020
-
Jurisdiction: United States District Court for the District of Delaware
-
Initial complaint: Natera alleges infringement by CareDx, asserting that the latter's AlloSure and other transplant diagnostics violate patents
-
Defendant's response: CareDx denied infringement and filed a motion to dismiss in June 2020, arguing invalidity and non-infringement
-
Summary judgment motions: Filed in late 2021, focusing on patent validity and infringement issues
-
Trial date: Not set as of the latest update; case remains in pre-trial phases
What are the core patent claims involved?
- ’284 Patent: Covers methods for detecting donor-derived cell-free DNA, emphasizing the techniques for analyzing DNA fragments within patient blood samples
- ’519 Patent: Extends claims to specific methods for assessing organ transplant rejection risk based on DNA analysis
Both patents aim to protect proprietary techniques used in non-invasive organ monitoring tests.
What are the legal issues?
- Infringement: Natera claims CareDx's products use methods covered by the patents
- Invalidity defenses: CareDx argues the patents are invalid due to prior art, obviousness, or failure to satisfy patentability criteria
- Damages and injunctive relief: Natera seeks monetary damages and an order to halt sales of infringing products if infringement is established
What is the current status?
- No final ruling has been issued
- The case is at the summary judgment stage, with the court reviewing patent validity and infringement allegations
- Both parties are engaged in discovery, including depositions and document exchanges
Enforcement and market implications
- Litigation underscores patent disputes in the molecular diagnostics sector
- A ruling in favor of Natera could restrict CareDx’s current product offerings
- Conversely, a ruling favoring CareDx could challenge Natera's patent protections
Analysis: Strategic and Industry Impact
The case demonstrates the aggressive patent enforcement in the organ transplant monitoring space, where proprietary methods give companies a competitive edge. Successful invalidation of patents could open the market, loosening intellectual property protections. Conversely, affirming patent validity reinforces Natera's market position and deters imitators.
The ongoing case reflects broader patent disputes noting the push for innovation in non-invasive diagnostics. Courts' rulings could influence licensing strategies and R&D investments across the sector.
Key takeaways
- The litigation centers on Natera's patent rights over specific cell-free DNA testing methods used in transplant monitoring
- Case remains unresolved, with motions and discovery ongoing
- Outcomes could influence patent protections, market share, and licensing dynamics in molecular diagnostics
- The case exemplifies heightened patent enforcement and litigation in biotech diagnostics
FAQs
1. What patents are involved in the Natera v. CareDx case?
Two patents: U.S. Patent No. 9,617,284 and U.S. Patent No. 10,552,519, covering methods of analyzing cell-free DNA for transplant monitoring.
2. What are the main legal defenses raised by CareDx?
CareDx argues the patents are invalid due to prior art, obviousness, or failure to meet patentability criteria.
3. How could a ruling affect the diagnostics market?
A ruling for Natera could limit CareDx’s product offerings, while a ruling for CareDx might weaken patent protections, potentially opening the market for competitors.
4. What is the status of the litigation?
The case is at the summary judgment phase; no final decision has been issued.
5. When is a final resolution expected?
No specific timeline is available; the case remains in pre-trial procedural stages.
References
[1] Court docket and filings, District of Delaware, Case 1:20-cv-00038
